Manganese-peptide Countermeasures for Radiation Exposure

Information

  • Research Project
  • 9619868
  • ApplicationId
    9619868
  • Core Project Number
    R43AI140809
  • Full Project Number
    1R43AI140809-01
  • Serial Number
    140809
  • FOA Number
    PA-15-065
  • Sub Project Id
  • Project Start Date
    9/11/2018 - 5 years ago
  • Project End Date
    8/31/2019 - 4 years ago
  • Program Officer Name
    RIOS, CARMEN I
  • Budget Start Date
    9/11/2018 - 5 years ago
  • Budget End Date
    8/31/2019 - 4 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/11/2018 - 5 years ago

Manganese-peptide Countermeasures for Radiation Exposure

The toxicity of ionizing radiation (IR) in diverse cell-types is associated with a high susceptibility of the proteome to oxidative modification. Proteome protection as a tactic for IR survival was recently applied to mice using a synthetic Mn-peptide antioxidant complex (MDP) that specifically prevents protein oxidation and preserves the activity of irradiated enzymes, including those for cellular DNA repair. MDP, adapted from the radioresistant bacterium Deinococcus radiodurans , is nontoxic and protects mice from acute radiation syndromes (ARS). When administered pre- and post-irradiation, all the mice treated with MDP survived 9.5 Gy (LD70/30). MDP diminished ARS and increased serum levels of IL-3, G-CSF and GM-CSF. The radioprotective efficacy of MDP administered to mice post-irradiation, however, remains untested. Note, there is good reason to think that post-exposure treatment alone with MDP will be radioprotective: MDP protects human Jurkat T-cells exposed to 100 Gy when administered 4 hours post-irradiation. We propose to determine whether MDP could serve as an IR countermeasure when administered starting 24, 48, or 72 hours after exposure to x-ray irradiation. The MDP complex will be tested in a standard mouse model for total body irradiation induced ARS (controlled for age and diet), focusing on tissue- and immunological-functions among the survivors.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    299372
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:299372\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOLOGICAL MIMETICS, INC.
  • Organization Department
  • Organization DUNS
    944050277
  • Organization City
    FREDERICK
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    217028717
  • Organization District
    UNITED STATES